Sale!

CFH Gene Hemolytic Uremic Syndrome Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The CFH Gene Hemolytic Uremic Syndrome Genetic Test is a specialized diagnostic tool designed to detect mutations in the CFH gene, which are known to be associated with atypical Hemolytic Uremic Syndrome (aHUS). This condition is a rare, life-threatening disorder characterized by the triad of hemolytic anemia, thrombocytopenia (low platelet count), and acute renal failure. The CFH gene plays a critical role in regulating the complement system, part of the body’s immune response. Mutations in this gene can lead to uncontrolled complement activation, resulting in the damage to the endothelial cells lining the blood vessels, particularly affecting the kidneys.

Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test is aimed at individuals who have symptoms of aHUS, have a family history of the condition, or are in need of a definitive diagnosis to guide treatment decisions. The test involves collecting a blood sample from the patient, which is then analyzed using advanced genetic sequencing techniques to identify any mutations in the CFH gene.

The cost of the CFH Gene Hemolytic Uremic Syndrome Genetic Test at DNA Labs UAE is 4400 AED. Given the complexity of the condition and the potential for targeted treatment options, the test represents a critical step in the management of patients with suspected or confirmed aHUS. Early and accurate diagnosis can significantly influence the course of treatment and improve patient outcomes, making this test a valuable resource for affected individuals and their families.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CFH Gene Hemolytic Uremic Syndrome Genetic Test

At DNA Labs UAE, we offer the CFH Gene Hemolytic Uremic Syndrome Genetic Test at a cost of AED 4400.0. This test is used to diagnose and identify genetic mutations associated with hemolytic uremic syndrome (HUS), a rare condition characterized by the destruction of red blood cells, kidney failure, and low platelet count.

Test Components and Sample Condition

The CFH Gene Hemolytic Uremic Syndrome Genetic Test requires either blood, extracted DNA, or one drop of blood on an FTA card as a sample condition.

Report Delivery and Method

The test results will be delivered within 3 to 4 weeks using NGS (Next-Generation Sequencing) technology.

Test Type and Test Department

This test falls under the categories of Hepatology, Nephrology, and Endocrinology Disorders. It is performed in our Genetics department.

Referring Doctor

The CFH Gene Hemolytic Uremic Syndrome Genetic Test can be requested by a General Physician.

Pre Test Information

Prior to the test, it is essential to provide the clinical history of the patient who is undergoing the CFH Gene Hemolytic Uremic Syndrome Genetic Test. Additionally, a Genetic Counselling session is recommended to draw a pedigree chart of family members affected by CFH Gene Hemolytic Uremic Syndrome.

Test Details

The CFH gene, also known as complement factor H gene, is associated with a genetic predisposition to atypical hemolytic uremic syndrome (aHUS). Mutations in this gene can disrupt the regulation of the complement system, which plays a role in the immune response and inflammation. Dysregulation of the complement system can lead to the destruction of red blood cells and the development of HUS.

NGS genetic testing, utilizing advanced sequencing technologies, can analyze multiple genes simultaneously. In the case of hemolytic uremic syndrome, NGS genetic testing can identify mutations in the CFH gene and other genes linked to aHUS. This information aids in the diagnosis and management of individuals suspected of having a genetic predisposition to HUS.

By identifying specific genetic mutations, NGS genetic testing provides crucial information for healthcare professionals to better comprehend the underlying cause of hemolytic uremic syndrome. This information guides treatment decisions, predicts the risk of recurrence, and allows for genetic counseling for affected individuals and their families.

Test Name CFH Gene Hemolytic uremic syndrome Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Hepatology Nephrology Endocrinology Disorders
Doctor General Physician
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CFH Gene Hemolytic uremic syndrome NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CFH Gene Hemolytic uremic syndrome NGS Genetic DNA Test gene CFH
Test Details

Hemolytic uremic syndrome (HUS) is a rare condition characterized by the destruction of red blood cells, kidney failure, and low platelet count. It is usually caused by an infection, most commonly by certain strains of E. coli bacteria.

The CFH gene, also known as complement factor H gene, is associated with a genetic predisposition to atypical hemolytic uremic syndrome (aHUS). Mutations in this gene can disrupt the regulation of the complement system, which is involved in the immune response and inflammation. Dysregulation of the complement system can lead to the destruction of red blood cells and the development of HUS.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technologies to analyze multiple genes simultaneously. In the context of hemolytic uremic syndrome, NGS genetic testing can be used to identify mutations in the CFH gene and other genes associated with aHUS. This information can help in the diagnosis and management of individuals with a suspected genetic predisposition to HUS.

By identifying specific genetic mutations, NGS genetic testing can provide important information for healthcare professionals to better understand the underlying cause of hemolytic uremic syndrome in an individual. This information can help guide treatment decisions, predict the risk of recurrence, and provide genetic counseling for affected individuals and their families.